Bayesian Tools for PBPK Models in Drug Interaction Res.

药物相互作用研究中 PBPK 模型的贝叶斯工具。

• 批准号: 7230428
• 负责人: Lang Li
• 金额: $ 25.86万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7230428
• 关键词: Active Sites; Address; Animals; Applications Grants; Area; Bayesian Method; Bayesian Prediction; CYP3A4 gene; Clinical; Clinical Data; Complex; Computational algorithm; Computer software; Computers; Condition; Data; Drug Interactions; Drug Kinetics; Enterocytes; Enzymes; Equation; Hand; Health system; Hepatocyte; Human; In Vitro; Individual; Joints; Ketoconazole; Knowledge; Maps; Meta-Analysis; Methods; Midazolam; Modeling; Morbidity - disease rate; Noise; Online Systems; Organ; Performance; Pharmaceutical Preparations; Phase; Physiological; Plasma; Poison; Population; Procedures; Process; Public Health; Publishing; Range; Rate; Reaction; Research; Research Personnel; Sampling; Scientist; Site; Software Validation; Solutions; Source; Staging; Statistical Methods; Structure; Substrate Interaction; System; Therapeutic Equivalency; Time; Tissues; Uncertainty; Update; Variant; base; cost; cytochrome P450 3A; design; human data; in vivo; inhibitor/antagonist; mortality; pharmacokinetic model; predictive modeling; success; tool; web based interface

DESCRIPTION (provided by applicant): In drug-drug interaction (DDI) research, to fully understand multiple drugs' pharmacokinetics and their interactions, a physiologically based pharmacokinetic model (PBPK) is the only viable means of investigating and quantifying all the interacting factors (active sites or organs). A PBPK model is known for its model identification problem because of its complex structure; hence, it usually borrows prior physiological information to make the model identifiable. However, conventional DDI researches based on deterministic PBPK models ignore population variations in PK parameters, experimental noise and uncertainties in prior knowledge, which in turn leads to subjective conclusions with unknown reliability. This grant application proposes a system of Bayesian tools to meet these pharmacological, statistical and computational challenges of PBPK models by exploring three aims. In Aim 1, individual drug's PBPK models of the inhibitor-substrate combination is established based on their published animal, in-vitro, and in-vivo data; the strategy of starting a simple model with limited information to a complex model with rich knowledge is systematically discussed; and Bayesian meta-analysis methods are proposed. In Aim 2, based on clinical DDI studies, a two-stage Bayesian method for a joint inhibitor-substrate PBPK model is developed; a predictive false negative rate is proposed to evaluate the DDI prediction; and Bayesian model selection procedures are implemented to select the best PBPK model among competitive ones. In Aim 3, all the prescribed Bayesian tools are implemented in R, a statistical and computational freeware; and its web-based application is developed to facilitate its usage for general research scientists. In this grant application, we realize the fact that the DDI is enzyme-dependent. Hence, a CYP3A specific inhibitor-substrate combination, ketoconazole-midazolam, is chosen as a starting example. It will serve as a building block for multi-enzyme and multi-drug based DDI PBPK models.

描述（申请人提供）：在药物相互作用（DDI）研究中，为了充分了解多种药物的药代动力学及其相互作用，基于生理学的药代动力学模型（PBPK）是研究和量化所有相互作用因素（活性部位或器官）的唯一可行方法。PBPK模型由于其复杂的结构而以其模型识别问题而闻名;因此，它通常借用先前的生理信息来使模型可识别。然而，传统的基于确定性PBPK模型的DDI研究忽略了PK参数的群体变异性、实验噪声和先验知识的不确定性，从而导致得出可信度未知的主观结论。该资助申请提出了一个贝叶斯工具系统，通过探索三个目标来满足PBPK模型的药理学，统计学和计算挑战。在目标1中，基于已发表的动物、体外和体内数据，建立了单个药物的代谢物-底物组合的PBPK模型;系统地讨论了从具有有限信息的简单模型到具有丰富知识的复杂模型的策略;并提出了贝叶斯荟萃分析方法。目的2基于临床DDI研究，提出了一种两阶段贝叶斯方法用于联合靶-底物PBPK模型;提出了一种预测假阴性率来评估DDI预测;并实施贝叶斯模型选择程序以在竞争模型中选择最佳PBPK模型。在目标3中，所有规定的贝叶斯工具都在R中实现，R是一个统计和计算免费软件;它的基于Web的应用程序被开发出来，以方便一般研究科学家使用。在本申请中，我们认识到DDI是酶依赖性的。因此，选择CYP 3A特异性底物-底物组合酮康唑-咪达唑仑作为起始实例。它将作为基于多酶和多药物的DDI PBPK模型的构建模块。